Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study

Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 20; no. 1; pp. 1 - 10
Main Authors Ning, Houxu, Zhou, Hao, Ren, Jingru, Zhou, Gaiyan, Yang, Ning, Wang, Zhenfu, Yuan, Canxing, Tian, Zuojun, Chen, Juping, Shen, Lihua, Zheng, Huifen, Zhao, Yang, Wang, Haidong, Liu, Weiguo, Liu, Zhenguo
Format Journal Article
LanguageEnglish
Published London BioMed Central 12.08.2022
BioMed Central Ltd
BMC
Subjects
Biomedical and Life Sciences
Biomedicine
Care and treatment
Chi-square test
Clinical trials
Complications and side effects
Depression in the Parkinson's disease
Depression, Mental
Development and progression
Double-blind studies
Drug dosages
Herbal medicine
Medicine, Chinese
Medicine/Public Health
Mental depression
Methods
Movement disorders
Neurodegenerative diseases
Neuroscience
Parkinson's disease
Patient outcomes
Patients
Pharmaceuticals
Placebos
Pramipexole
Quality of life
Randomized controlled trial
Remission
Remission (Medicine)
Statistical analysis
Zishen Pingchan granules
China
Depression in the Parkinson's disease
Randomized controlled trial
Pramipexole
Zishen Pingchan granules
Online AccessGet full text
ISSN1479-5876
1479-5876
DOI10.1186/s12967-022-03551-z

Cover

Abstract Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD). Methods A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG ( n  = 100) or placebo ( n  = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks. Results After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (− 1.43 scores [− 2.50, − 0.36]; p  = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p  = 0.041; 34.8% vs. 18.4%; p  = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (− 3.56 scores [− 5.77, − 1.35]; p  = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated. Conclusion ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432
AbstractList Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD).BACKGROUND AND OBJECTIVEZishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD).A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks.METHODSA 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks.After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (- 1.43 scores [- 2.50, - 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (- 3.56 scores [- 5.77, - 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated.RESULTSAfter 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (- 1.43 scores [- 2.50, - 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (- 3.56 scores [- 5.77, - 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated.ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432.CONCLUSIONZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432.
Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD). A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks. After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (- 1.43 scores [- 2.50, - 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (- 3.56 scores [- 5.77, - 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated. ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients.
Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD). Methods A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks. Results After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (− 1.43 scores [− 2.50, − 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (− 3.56 scores [− 5.77, − 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated. Conclusion ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432
Abstract Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD). Methods A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks. Results After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (− 1.43 scores [− 2.50, − 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (− 3.56 scores [− 5.77, − 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated. Conclusion ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432
Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD). Methods A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG ( n  = 100) or placebo ( n  = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks. Results After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (− 1.43 scores [− 2.50, − 0.36]; p  = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p  = 0.041; 34.8% vs. 18.4%; p  = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (− 3.56 scores [− 5.77, − 1.35]; p  = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated. Conclusion ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; http://www.chictr.org.cn/showproj.aspx?proj=30432
Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on drug with some antiparkinsonian drugs in China. The objectives of this study were to evaluate the efficacy, safety, and tolerability of ZPG combined with pramipexole in the treatment of depression in PD (dPD). Methods A 12-week, multicenter, randomized, double-blind, and placebo-controlled study on ZPG was performed on a total of 200 patients who were treated with pramipexole but still had mild to moderate depressive symptoms. Patients were randomly divided into ZPG (n = 100) or placebo (n = 100). The primary effective result was the mean change from the baseline on the Hamilton Depression Scale 17 items (HAM-D-17) over 12 weeks and the clinical efficacy rate. Secondary endpoints were the mean change from the baseline in the Geriatric Depression Scale (GDS-15), Unified Parkinson's disease rating scale Part III (UPDRS III), Parkinson's quality of life scale (PDQ-8), and Parkinson's disease sleep scale (PDSS-2) over 12 weeks. Results After 12 weeks of treatment, ZPG significantly reduced the mean [95% confidence interval] HAMD score vs. placebo (- 1.43 scores [- 2.50, - 0.36]; p = 0.009). The clinical remission rate and responders of the ZPG group were higher than those of the placebo (46.1% vs. 31.0%; p = 0.041; 34.8% vs. 18.4%; p = 0.014). A significant improvement in the PDSS-2 score was also observed in the ZPG group compared with that in the placebo group (- 3.56 scores [- 5.77, - 1.35]; p = 0.002). A total of 7 patients (7.1%) in the ZPG group had mild adverse events (AEs) vs 9 patients (9%) in the placebo group. No severe AEs were observed in either group. The randomization and controlled clinical study revealed that ZPG was effective, safe, and well-tolerated. Conclusion ZPG combined with pramipexole further reduced the depressive symptoms and improved the sleeping quality of PD patients. Trial registration The protocol was retrospectively registered at the Chinese Clinical Trial Registry, Unique identifier: ChiCTR1800019942, date of registration: December 9, 2018; Keywords: Depression in the Parkinson's disease, Zishen Pingchan granules, Pramipexole, Randomized controlled trial
ArticleNumber 357
Audience Academic
Author Tian, Zuojun
Ning, Houxu
Wang, Zhenfu
Liu, Weiguo
Shen, Lihua
Chen, Juping
Zheng, Huifen
Zhou, Hao
Liu, Zhenguo
Wang, Haidong
Ren, Jingru
Yuan, Canxing
Zhao, Yang
Zhou, Gaiyan
Yang, Ning
Author_xml – sequence: 1
  givenname: Houxu
  surname: Ning
  fullname: Ning, Houxu
  organization: Department of Chinese Medicine, The Affiliated Brain Hospital of Nanjing Medical University, Department of Neurology, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine
– sequence: 2
  givenname: Hao
  surname: Zhou
  fullname: Zhou, Hao
  organization: Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University
– sequence: 3
  givenname: Jingru
  surname: Ren
  fullname: Ren, Jingru
  organization: Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University
– sequence: 4
  givenname: Gaiyan
  surname: Zhou
  fullname: Zhou, Gaiyan
  organization: Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University
– sequence: 5
  givenname: Ning
  surname: Yang
  fullname: Yang, Ning
  organization: Department of Chinese Medicine, The Affiliated Brain Hospital of Nanjing Medical University
– sequence: 6
  givenname: Zhenfu
  surname: Wang
  fullname: Wang, Zhenfu
  organization: Department of Neurology, Chinese PLA General Hospital
– sequence: 7
  givenname: Canxing
  surname: Yuan
  fullname: Yuan, Canxing
  organization: Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
– sequence: 8
  givenname: Zuojun
  surname: Tian
  fullname: Tian, Zuojun
  organization: Department of Neurology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University
– sequence: 9
  givenname: Juping
  surname: Chen
  fullname: Chen, Juping
  organization: Department of Neurology, Changshu Hospital of Traditional Chinese Medicine
– sequence: 10
  givenname: Lihua
  surname: Shen
  fullname: Shen, Lihua
  organization: Department of Neurology, Affiliated Hospital of Nantong University, Nantong University
– sequence: 11
  givenname: Huifen
  surname: Zheng
  fullname: Zheng, Huifen
  organization: Department of Neurology, Geriatric Hospital of Nanjing Medical University, Nanjing Medical University
– sequence: 12
  givenname: Yang
  surname: Zhao
  fullname: Zhao, Yang
  organization: Department of Neurology, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine
– sequence: 13
  givenname: Haidong
  surname: Wang
  fullname: Wang, Haidong
  organization: Department of Chinese Medicine, The Affiliated Brain Hospital of Nanjing Medical University
– sequence: 14
  givenname: Weiguo
  orcidid: 0000-0001-5916-9837
  surname: Liu
  fullname: Liu, Weiguo
  email: wgliunbh@sina.com
  organization: Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University
– sequence: 15
  givenname: Zhenguo
  surname: Liu
  fullname: Liu, Zhenguo
  email: zhenguoliu2011@aliyun.com
  organization: Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
BookMark eNp9kstu1TAQhiNURC_wAqwssYBFUxzbuZgFUlVxqVQJFrBhYzn25BwXxw52UmifjwdjTk9RaYWqSHEy-f_PGc-_X-yEGKAonlf0qKq65nWumGzakjJWUl7XVXn1qNirRCvLumubnX-ed4v9nM8pZaIW8kmxy2vZMC7kXvH7m8trCGRyYWXWOpBV0mHxkImJY-8CWPLTzWsyJT26CX5FD8QFMq9xGacUL2CEMJM4EAtTgpzdBZB8OU5zHPNG-Vmn7y7kGF5mYl0GneEN0ciLeQIzo_yQjIufnUEOpEOC-9s4uiuwh8TGpfdQ9t4FfDMxzCl6j_9ksOKM9iTPi718WjwetM_w7GY9KL6-f_fl5GN59unD6cnxWWnqTsyl6QQ0vIKuErTuoWeDaU2H965rNQfBBg1U1x00jeAUBbJphka2g2Qdo1Tzg-J0y7VRn6spuVGnSxW1U9eFmFZKJ-zEgzK8Z7wfmJZWClOzTtYtjsP0iBqstsh6u2VNSz-C3XSftL8DvfsluLVaxQslecuFoAh4dQNI8ccCeVajywa81wHikhVrKavajosKpS_uSc_jkgIe1UYlaCtkRW9VK40NuDBE3NdsoOq4rTiiMDOoOvqPCi8Lo8MJweCwfsfQbQ0GR54TDMq4Wc9uM0ztvKqo2qRZbdOsMM3qOs3qCq3snvXv8Txo4ltTRnFYQbpt9gHXH-AxDZc
CitedBy_id crossref_primary_10_3389_fcimb_2023_1121445
crossref_primary_10_1016_j_exger_2023_112295
crossref_primary_10_1021_acsomega_3c04312
crossref_primary_10_1097_st9_0000000000000009
crossref_primary_10_1097_MD_0000000000034425
crossref_primary_10_4103_NRR_NRR_D_23_01240
crossref_primary_10_1007_s44169_024_00059_z
crossref_primary_10_3390_ph17060689
crossref_primary_10_1007_s12035_024_04584_9
Cites_doi 10.1016/j.brainresbull.2021.10.015
10.1001/jama.2013.281053
10.1016/j.schres.2009.12.027
10.1186/s13020-019-0254-9
10.1021/acschemneuro.0c00332
10.1002/mds.21966
10.1016/S0254-6272(17)30051-1
10.1093/brain/awh445
10.1016/j.neuropharm.2009.05.001
10.1016/S1474-4422(10)70106-X
10.1016/j.joim.2020.12.006
10.1002/bmc.3371
10.1016/j.jad.2013.04.028
10.1016/j.jep.2021.114586
10.1016/j.coph.2008.12.002
10.1002/mds.26424
10.4103/1673-5374.235075
10.1002/mds.23469
10.1038/nrn.2017.62
10.1124/pr.110.002642
10.1523/JNEUROSCI.4035-08.2008
10.1002/mds.27602
10.1007/s12272-021-01337-3
10.1161/CIRCULATIONAHA.115.019902
10.1111/j.1532-5415.2004.52219.x
10.1046/j.1468-1331.2003.00612.x
10.1016/j.brainres.2008.02.009
10.1016/j.neuint.2020.104730
10.1016/j.mcna.2018.10.014
10.1002/mds.27438
10.1080/14656566.2019.1612877
10.3390/biom10050792
ContentType Journal Article
Copyright The Author(s) 2022
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
Copyright_xml – notice: The Author(s) 2022
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
DBID C6C
AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-022-03551-z
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 10
ExternalDocumentID oai_doaj_org_article_c3b23bf2a9d94c528957147cb282fdad
PMC9373440
A713783623
10_1186_s12967_022_03551_z
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Special Project for the Development of traditional Chinese Medicine Science and Technology in Jiangsu Province
  grantid: 2020ZX17
– fundername: National Key Research and Development Program of China
  grantid: 2017YFC1310302
– fundername: ;
  grantid: 2020ZX17
– fundername: ;
  grantid: 2017YFC1310302
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
AAYXX
ALIPV
CITATION
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c584t-c84e631e81405beb2fc7c82fc887a3e42fae0a58e66430beb966f697f928200a3
IEDL.DBID 7X7
ISSN 1479-5876
IngestDate Wed Aug 27 01:32:01 EDT 2025
Thu Aug 21 18:26:39 EDT 2025
Fri Sep 05 04:14:15 EDT 2025
Sun Sep 07 03:44:10 EDT 2025
Tue Jun 17 20:27:21 EDT 2025
Tue Jun 10 20:37:01 EDT 2025
Tue Jul 01 02:59:36 EDT 2025
Thu Apr 24 22:58:25 EDT 2025
Sat Sep 06 07:28:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Depression in the Parkinson's disease
Randomized controlled trial
Pramipexole
Zishen Pingchan granules
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c584t-c84e631e81405beb2fc7c82fc887a3e42fae0a58e66430beb966f697f928200a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-5916-9837
OpenAccessLink https://www.proquest.com/docview/2704074910?pq-origsite=%requestingapplication%
PMID 35962349
PQID 2704074910
PQPubID 43076
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_c3b23bf2a9d94c528957147cb282fdad
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9373440
proquest_miscellaneous_2702178341
proquest_journals_2704074910
gale_infotracmisc_A713783623
gale_infotracacademiconefile_A713783623
crossref_citationtrail_10_1186_s12967_022_03551_z
crossref_primary_10_1186_s12967_022_03551_z
springer_journals_10_1186_s12967_022_03551_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-12
PublicationDateYYYYMMDD 2022-08-12
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-12
  day: 12
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of translational medicine
PublicationTitleAbbrev J Transl Med
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References D Weintraub (3551_CR4) 2004; 52
I Rektorova (3551_CR6) 2003; 10
HQ Wang (3551_CR35) 2021; 281
B Pan (3551_CR19) 2008; 28
RB Postuma (3551_CR13) 2015; 30
SM Wilson (3551_CR24) 2020; 11
SG Reich (3551_CR1) 2019; 103
M Zimmerman (3551_CR14) 2013; 150
SC Gu (3551_CR31) 2022; 13
D Devos (3551_CR30) 2008; 23
AHV Schapira (3551_CR2) 2017; 18
G Vieira (3551_CR21) 2020; 10
J Liu (3551_CR18) 2009; 57
P Barone (3551_CR7) 2010; 9
M Ryan (3551_CR3) 2019; 20
L Xiang (3551_CR20) 2008; 1207
P Barone (3551_CR5) 2006; 253
A. (3551_CR11) 2013; 310
F Zhang (3551_CR33) 2015; 29
SC Gu (3551_CR9) 2021; 19
LA Glantz (3551_CR25) 2010; 118
RJ Mentz (3551_CR12) 2016; 133
A Quattrone (3551_CR29) 2018; 33
Y Bang (3551_CR15) 2021; 44
Q Ye (3551_CR26) 2014; 2014
MM Wickremaratchi (3551_CR36) 2011; 26
C De Mei (3551_CR28) 2009; 9
JM Beaulieu (3551_CR22) 2011; 63
P Remy (3551_CR16) 2005; 128
SZ Wei (3551_CR23) 2021; 177
M Zhong (3551_CR34) 2019; 14
M Fatima (3551_CR27) 2020; 136
K Seppi (3551_CR8) 2019; 34
Q Ye (3551_CR10) 2018; 13
ZW Chen (3551_CR32) 2020; 19
Q Ye (3551_CR17) 2017; 37
References_xml – volume: 177
  start-page: 363
  year: 2021
  ident: 3551_CR23
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2021.10.015
– volume: 310
  start-page: 2191
  issue: 20
  year: 2013
  ident: 3551_CR11
  publication-title: JAMA
  doi: 10.1001/jama.2013.281053
– volume: 118
  start-page: 292
  issue: 1–3
  year: 2010
  ident: 3551_CR25
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2009.12.027
– volume: 14
  start-page: 37
  year: 2019
  ident: 3551_CR34
  publication-title: Chin Med
  doi: 10.1186/s13020-019-0254-9
– volume: 11
  start-page: 2506
  issue: 17
  year: 2020
  ident: 3551_CR24
  publication-title: ACS Chem Neurosci
  doi: 10.1021/acschemneuro.0c00332
– volume: 23
  start-page: 850
  issue: 6
  year: 2008
  ident: 3551_CR30
  publication-title: Mov Disord
  doi: 10.1002/mds.21966
– volume: 37
  start-page: 244
  issue: 2
  year: 2017
  ident: 3551_CR17
  publication-title: J Tradit Chin Med
  doi: 10.1016/S0254-6272(17)30051-1
– volume: 128
  start-page: 1314
  issue: Pt 6
  year: 2005
  ident: 3551_CR16
  publication-title: Brain
  doi: 10.1093/brain/awh445
– volume: 57
  start-page: 164
  issue: 2
  year: 2009
  ident: 3551_CR18
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2009.05.001
– volume: 9
  start-page: 573
  issue: 6
  year: 2010
  ident: 3551_CR7
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(10)70106-X
– volume: 19
  start-page: 120
  issue: 2
  year: 2021
  ident: 3551_CR9
  publication-title: J Integr Med
  doi: 10.1016/j.joim.2020.12.006
– volume: 29
  start-page: 890
  issue: 6
  year: 2015
  ident: 3551_CR33
  publication-title: Biomed Chromatogr
  doi: 10.1002/bmc.3371
– volume: 150
  start-page: 384
  issue: 2
  year: 2013
  ident: 3551_CR14
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2013.04.028
– volume: 281
  year: 2021
  ident: 3551_CR35
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2021.114586
– volume: 2014
  year: 2014
  ident: 3551_CR26
  publication-title: Evid Based Complement Alternat Med
– volume: 9
  start-page: 53
  issue: 1
  year: 2009
  ident: 3551_CR28
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2008.12.002
– volume: 30
  start-page: 1591
  issue: 12
  year: 2015
  ident: 3551_CR13
  publication-title: Mov Disord
  doi: 10.1002/mds.26424
– volume: 253
  start-page: 601
  issue: 5
  year: 2006
  ident: 3551_CR5
  publication-title: Pramipexole versus sertraline in the treatment of depression in Parkinson's disease
– volume: 13
  start-page: 1269
  issue: 7
  year: 2018
  ident: 3551_CR10
  publication-title: Neural Regen Res
  doi: 10.4103/1673-5374.235075
– volume: 26
  start-page: 457
  issue: 3
  year: 2011
  ident: 3551_CR36
  publication-title: Mov Disord
  doi: 10.1002/mds.23469
– volume: 18
  start-page: 435
  issue: 7
  year: 2017
  ident: 3551_CR2
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn.2017.62
– volume: 63
  start-page: 182
  issue: 1
  year: 2011
  ident: 3551_CR22
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.110.002642
– volume: 28
  start-page: 14018
  issue: 52
  year: 2008
  ident: 3551_CR19
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.4035-08.2008
– volume: 34
  start-page: 180
  issue: 2
  year: 2019
  ident: 3551_CR8
  publication-title: Mov Disord
  doi: 10.1002/mds.27602
– volume: 44
  start-page: 588
  issue: 6
  year: 2021
  ident: 3551_CR15
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-021-01337-3
– volume: 133
  start-page: 872
  issue: 9
  year: 2016
  ident: 3551_CR12
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.115.019902
– volume: 19
  start-page: 2326
  issue: 3
  year: 2020
  ident: 3551_CR32
  publication-title: Exp Ther Med
– volume: 52
  start-page: 784
  issue: 5
  year: 2004
  ident: 3551_CR4
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2004.52219.x
– volume: 10
  start-page: 399
  issue: 4
  year: 2003
  ident: 3551_CR6
  publication-title: Eur J Neurol
  doi: 10.1046/j.1468-1331.2003.00612.x
– volume: 13
  year: 2022
  ident: 3551_CR31
  publication-title: Placebo-Controlled Study Front Pharmacol
– volume: 1207
  start-page: 214
  year: 2008
  ident: 3551_CR20
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2008.02.009
– volume: 136
  year: 2020
  ident: 3551_CR27
  publication-title: Neurochem Int
  doi: 10.1016/j.neuint.2020.104730
– volume: 103
  start-page: 337
  issue: 2
  year: 2019
  ident: 3551_CR1
  publication-title: Med Clin North Am
  doi: 10.1016/j.mcna.2018.10.014
– volume: 33
  start-page: 1213
  issue: 8
  year: 2018
  ident: 3551_CR29
  publication-title: Mov Disord
  doi: 10.1002/mds.27438
– volume: 20
  start-page: 1351
  issue: 11
  year: 2019
  ident: 3551_CR3
  publication-title: Expert Opin Pharmacother
  doi: 10.1080/14656566.2019.1612877
– volume: 10
  start-page: 5
  year: 2020
  ident: 3551_CR21
  publication-title: Biomolecules
  doi: 10.3390/biom10050792
SSID ssj0024549
Score 2.4018126
Snippet Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on...
Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on...
Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson's disease (PD), is usually used as an add-on drug with some...
Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as an add-on...
Abstract Background and objective Zishen Pingchan granule (ZPG), a traditional Chinese herbal recipe for treating Parkinson’s disease (PD), is usually used as...
SourceID doaj
pubmedcentral
proquest
gale
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Biomedical and Life Sciences
Biomedicine
Care and treatment
Chi-square test
Clinical trials
Complications and side effects
Depression in the Parkinson's disease
Depression, Mental
Development and progression
Double-blind studies
Drug dosages
Herbal medicine
Medicine, Chinese
Medicine/Public Health
Mental depression
Methods
Movement disorders
Neurodegenerative diseases
Neuroscience
Parkinson's disease
Patient outcomes
Patients
Pharmaceuticals
Placebos
Pramipexole
Quality of life
Randomized controlled trial
Remission
Remission (Medicine)
Statistical analysis
Zishen Pingchan granules
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pj5UwEG_MHowX49-IrqYmJnvwkQVaoHhbjZuNyXpyk42Xpi2DkvDg5fGecd_n2w_mTIGnuFEvHoEB2s505jftzJSxV4hS0UpZGypl0UGxsQmNy2XohIuA4jAAKFH4_GN2diE_XKaXvxz1RTFhQ3ngYeCOnbCJsFViirKQLkX_IM1jmTuLvkJVmpK0b1REkzM1VdlDt2dKkVHZcY9WDRUCRa5HaGDjcDczQ75a_02dfDNO8rfNUm-DTu-xuyN45CdDo--zW9A-YLfPx-3xh-z6M0W4t5xyoCijl39BS7RtoOcoV-gCQ8lp3ZWv1mZZr-B71wCvW44YkNd-ccGvFfKu4lOA7Dfg_dVytemWPVFSjrRPFzvq-bi184Yb_F43ZWwuuA9RpL7AesHx_2W3rHdQLnjZbW0DoUVgi1djjHyDbZqyM7mvdfuIXZy-__TuLByPaQgdopdN6JSETMRAtbNSi5565XKHzHGov4wAmVQGIpMqyBD9REiAHlaVFXlVIAujyIjH7KDtWnjCuKlMaoxVoNIENbgwuYHMZgrvS-liGbB44pp2Yw1zOkqj0d6XUZkeOK2R09pzWu8C9nr_zmqo4PFX6rckDHtKqr7tb6BM6lEm9b9kMmBHJEqadAQ2z5kx1QE7SdW29EkeC8qeSUTADmeUOLfd_PEkjHrULb1OclS8uUScF7CX-8f0JsXLtdBtPQ36mgohSsDymRDPejZ_0tZffX1xRKxCSvz6YhL3nz__88g9_R8j94zdSfwsVWGcHLKDzXoLzxH1bewLP8F_AFSgWeU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeKL-InVUyII9-BW-5G2WUHkFI9DWJ9cOHwJSTo9C912bXflbv8-_zBnsu0e9c57KbSZtEkzk5lfMjNh7DVaqailjPGlNAhQTKh9bTPh29gGQH4YABQoPPuWnszF19PkdI8Nxx31P7C7FtrReVLztnp7_uviIwr8ByfwMn3Xoc5CcSe_9ADVZ-hvbrHbqJlSAmMzIS9z7yEYGgJnrq03Uk4uh__Vmfqq9-Q_W6hOMx3fZ_d6k5IfbXngAduD-iG7M-s3zR-xPz_I773mFBlFcb78DPXTuoKOI7chMIac02osX7Z6US7hvKmAlzVHy5CXbsnBrSDypuCD2-xv4N3FYrlqFh1RUuS0CyI77Hi_4fOea3xfM8RxTrhzXKS-QDvh-P28WZQbyCc8b9amAt-guYt3ved8hW0aYja5y4D7mM2Pv3z_fOL3hzf4Fm2alW-lgDQOgTJqJQbxe2EzK_GKs5qOQUSFhkAnElK0iQIkQNxVpNOsmCIIDAIdP2H7dVPDU8Z1oROtjQSZRDivxzrTkJpU4nMhbCg8Fg6jpmyf2ZwO2KiUQzgyVduRVjjSyo202njsza7OcpvX40bqT8QMO0rKye0eNO2Z6kVc2dhEsSkiPc2nwiaIZJMsFJk12KEi17nHDomVFPEyNs_qPgACO0k5uNRRFsYUUxPFHjsYUaLE23HxwIxqEBgVZTgdZwKtP4-92hVTTfKiq6FZOxpEoBINF49lIyYe9WxcUpc_XdZxtGNjIfDtk4HdLz_-_z_37Oa2Pmd3Iyd_0g-jA7a_atfwAq28lXnpRPcvG-5UVw
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96gvgifmLPUyII9-AW2yZtsr6dh8chnE8eHL6EJJ3qQrddtrtyt3-ff5gz2XbPeir4UmgzaZvOZD6S-U0Ze41eKlop52KtHQYoLrWx9UrGXvgEKA8DgIDCZ5-K03P58SK_6MvkEBbm1_37VBdvO7RHOJUp5zxB05jGm9vsTp6KImzMFsfXdfUw0BlAMX_sNzI8oT7_TS18MzPyt-3RYHVOHrD7vbvIj7b8fchuQfOI3T3rN8Qfsx9fKKe94YR6Igwv_4q2Z11Dx1GSMOiFktNKK18s7Xy2gMu2Bj5rOHp9fBaWE8LqIG8rPqTEfgfeXc0Xq3beESWhogNA7LDj_WbOO27xfu2A0ZzwkJRIY4HlhOPzy3Y-20A54WW7djXEDl1ZPOuz4mt8pwGPyUN12yfs_OTD5-PTuP8xQ-zRX1nFXksoRApULSt3GJtXXnmNR9RYVoDMKguJzTUU6O8kSIAxVVVMVTXFAC9JrHjK9pq2gWeM28rm1joNOs9QZwurLBSu0HhdSp_KiKUD14zvq5bTzzNqE6IXXZgtpw1y2gROm03E3uz6LLY1O_5J_Z6EYUdJ9bbDBRRD009f44XLhKsyOy2n0ucYpeYqlco7HFBV2jJihyRKhrQCvp63PbgBB0n1tcyRSgXhZTIRsYMRJc5mP24ehNH02qQzmUJVqyR6dhF7tWumnpQh10C7DjQYXWp0SiKmRkI8Gtm4pZl9CxXF0UcVUuLdJ4O4Xz_8719u___In7N7WZiPOk6zA7a3Wq7hBXp0K_cyTOWfdP9KUQ
  priority: 102
  providerName: Springer Nature
Title Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study
URI https://link.springer.com/article/10.1186/s12967-022-03551-z
https://www.proquest.com/docview/2704074910
https://www.proquest.com/docview/2702178341
https://pubmed.ncbi.nlm.nih.gov/PMC9373440
https://doaj.org/article/c3b23bf2a9d94c528957147cb282fdad
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9swUGwtjL2MfTJvXdBg0IfF1B-ypexlNKGlDFJGWSH0RUiy3AUSO4uTseX37YftTpETvLK-CGydbZ11ui_dnQj5AFoqSCmtQyE0GCg6VqEynIUmNZHFOAxrMVF4fJlfXLMvk2ziHW6ND6tseaJj1EVt0Ed-knAgN85Aun1e_Ajx1CjcXfVHaDwkh650GdAzn-wNLgbGT5soI_KTBmQbsAWMX49AzMbhpiOMXM3-u5z5brTkP1umThKdPyVPvApJT7dz_ow8sNVz8mjsN8lfkD83GOdeUcyEwrxeegvyaD2zDQVMwRC2BUXvK10s1Xy6sL_qmaXTioImSKfOxeA8hrQuaRsm-9PS5vd8sarnDUJiprRLGjtuqN_g-UQVvK9u8zb71AUqIi522afw_aKeTze26NOiXuuZDTWot3DlI-VnMKY2R5O6ircvyfX52bfRRegPawgN6DCr0Ahm8zS2WEEr02Cvl4YbAS1wMZValpTKRioTNgcdKAIAsLPKfMDLARh9UaTSV-Sgqiv7mlBVqkwpLazIEuDjqeLK5joXcJ8xE7OAxO2sSeMrmeOBGjPpLBqRy-1MS5hp6WZabgLycffMYlvH417oIRLDDhJrcLsb9fJW-iUtTaqTVJeJGhQDZjKwXDMeM240IFQWqgjIMZKSRE4BwzPKJzwAklhzS57yOMUcmiQNyFEHEla46Xa3xCg9h2nkfj0E5P2uG5_EqLnK1msHAxanAEUlILxDxB3Muj3V9LurMg56a8oYvL3fkvv-4___c2_uH-tb8jhx60-EcXJEDlbLtX0HWt1K99zS7ZHD4dnl1yu4GuWjnvOQQDtmAtqr4c1fnWdWLA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviE-RbYCRQHug0fLhJC4SQhts6thaIbRJ016M7TijUpuUpgXWP4q_gj-MOzdpFSb2tpdKjS-JnTvfh32_MyGvwEsFK6WUy7mCAEX50pU6Ya4OtWcwD8MYBAr3-nH3lH06i87WyO8aC4NplbVOtIo6LTSuke8ECYhbwsC6vR9_d_HUKNxdrY_QWIjFkbn8CSFb-e7wI_D3dRAc7J986LrVqQKuBmM7dTVnJg59g6WeIgWBZaYTzeEXppsMDQsyaTwZcRODsfaAAAKCLO4kWQeiE8-TITz3FllniGhtkfW9_f7nL6vqfhBu1dAcHu-UYE1BEWHGvAeG3XfnDfNnTwm4aguu5mf-s0lrbd_BfXKvclrp7kLKHpA1kz8kt3vVtvwj8uccM-tzitgrRBLTC7CAs6EpKXxbCL1NSnG9l44ncjQYm1_F0NBBTsH3pAO7qGHXKGmR0Tox94eh5eVoPC1GJVIiNtvC1LZLWm0pvaUSnlfUSNE2tamROBYzaVN4f1qMBnOTtmlazNTQuAocavhX5eYPoU81KpTaGruPyemNMPIJaeVFbp4SKjMZSam44VEAliOUiTSxijlcZ0z7zCF-zTWhq9rpeITHUNgYisdiwWkBnBaW02LukDfLe8aLyiHXUu-hMCwpseq3vVBMLkSlRIQOVRCqLJCdtMN0BLFylPgs0QoGlKUydcg2ipJA3QTd07KCWMAgscqX2E38EFE7QeiQrQYl6BTdbK6FUVQ6rRSrGeiQl8tmvBPz9HJTzCwNxLgcXCOHJA0hboys2ZIPvtm65uAph4zB09u1uK9e_v8vt3F9X1-QO92T3rE4PuwfbZK7gZ2L3PWDLdKaTmbmGfiUU_W8msiUfL1p3fEXSbKPFA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXxFOEFjASUg9s1DycxMutFFbl0YoDlSoulu1M2pV2k2izW8H-Pn4YM06yJRSQuKy08eThzNueb8LYS4xS0UsZ40tpMEExofa1zYRvYxsA1WEAEFD4-CQ9OhUfzpKzX1D8rtq935JsMQ3Upalc7td50aq4TPcb9FKo4FSJHqDDDP31TXZLkOuj7dr08KrbHqY_PVTmj-cN3JHr2n_dNl-vl_xt09T5oslddqcLIvlBy_V77AaU99n2cbdN_oD9-EqV7iUnLBQhe_k5eqTVDBqOU8VUGHJO66-8Xuj5tIZv1Qz4tOQYC_KpW2Rwa4a8KnhfKHsJvPk-r5fVvCFKwko72Nhew7stntdc4_WqHrk54q5UkeYCixHH--fVfLqGfMTzamVm4BtkAv7rauVn-Ew9SpO7nrcP2enk3ZfDI7_7XINvMYpZ-lYKSOMQqIdWYjBjL2xmJf6iHdMxiKjQEOhEQopRUIAEmGkV6Tgrxpj2BYGOH7GtsirhMeO60InWRoJMIrTksc40pCaVeFwIGwqPhT3XlO16mdMnNWbK5TQyVS2nFXJaOU6rtcdebc6p204e_6R-Q8KwoaQu3O5AtThXnVIrG5soNkWkx_lY2ARz1yQLRWYNTqjIde6xPRIlRbYCH8_qDvKAk6SuW-ogC2NC0USxx3YHlKjjdjjcC6PqbEyjogwNcCZQ6D32YjNMZ1LdXAnVytFgzikxVPFYNhDiwcyGI-X0wvUZx8g1FgKvPurF_ermf39zT_6P_Dnb_vx2oj69P_m4w25HTjWlH0a7bGu5WMFTDPmW5pnT6p9K31WF
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Zishen+pingchan+granules+combined+with+pramipexole+in+the+improvement+of+depressive+symptoms+in+Parkinson%27s+disease%3A+a+prospective%2C+multicenter%2C+randomized%2C+double-blind%2C+controlled+clinical+study&rft.jtitle=Journal+of+translational+medicine&rft.au=Houxu+Ning&rft.au=Zhou%2C+Hao&rft.au=Ren%2C+Jingru&rft.au=Zhou%2C+Gaiyan&rft.date=2022-08-12&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=20&rft.spage=1&rft_id=info:doi/10.1186%2Fs12967-022-03551-z
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon